Evidence map›Paper›PMID 29232489›Full record

ArticleChemMedChem2018

Achieving Biocompatible SABRE: An in vitro Cytotoxicity Study.

Anand Manoharan, Peter J Rayner, Wissam Iali, Michael J Burns, V Hugh Perry, Simon B Duckett

Abstract read
In one paragraph

Article in ChemMedChem, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. The journal of physical chemistry letters · 2024
    Article
  5. Article
  6. Article
  7. Iron-CatalyzedJournal of the American Chemical Society · 2023
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. RapidAnalytical chemistry · 2022
    Article
  13. SABRE hyperpolarized anticancer agents for use inMagnetic resonance in medicine · 2022
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Quantifying the effects of quadrupolar sinks viaChemical communications (Cambridge, England) · 2020
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Anand ManoharanDepartment of Chemistry, University of York, Heslington, York, YO10 5DD, UK.ORCID 0000-0002-8325-7375
Peter J RaynerDepartment of Chemistry, University of York, Heslington, York, YO10 5DD, UK.ORCID 0000-0002-6577-4117
Wissam IaliDepartment of Chemistry, University of York, Heslington, York, YO10 5DD, UK.ORCID 0000-0002-9428-2023
Michael J BurnsDepartment of Chemistry, University of York, Heslington, York, YO10 5DD, UK.ORCID 0000-0002-5569-1270
V Hugh PerrySchool of Biological Sciences, University of Southampton, Southampton, UK.ORCID 0000-0001-8950-5045
Simon B DuckettDepartment of Chemistry, University of York, Heslington, York, YO10 5DD, UK.ORCID 0000-0002-9788-6615

Funding

Wellcome TrustWellcome Trust 092506Wellcome Trust 098335
6 · The paper itself

Abstract

Production of a biocompatible hyperpolarized bolus for signal amplification by reversible exchange (SABRE) could open the door to simple clinical diagnosis via magnetic resonance imaging. Essential to successful progression to preclinical/clinical applications is the determination of the toxicology profile of the SABRE reaction mixture. Herein, we exemplify the cytotoxicity of the SABRE approach using in vitro cell assays. We conclude that the main cause of the observed toxicity is due to the SABRE catalyst. We therefore illustrate two catalyst removal methods: one involving deactivation and ion-exchange chromatography, and the second using biphasic catalysis. These routes produce a bolus suitable for future in vivo study.

Indexed as

Toxicity TestsBiocompatible MaterialsCatalysisCell Line, TumorCell SurvivalCoordination ComplexesHumansIridiumNicotinic AcidsSolventsBiocompatible MaterialsCoordination ComplexesIridiummethyl nicotinateNicotinic AcidsSolventsbiocompatibilitybiphasic catalysiscytotoxicityhyperpolarizationSABRE

Identifiers

PMID29232489
PMCPMC5838797

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.